The latter is already evident from the recent programmes that several drug companies have started on inflammation and associated processes for Alzheimer's disease, following the identification of TREM2 as a risk gene for this disorder. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.